TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Two patients described in a MedPage Today report received coverage approvals after contacting insurance company leaders over denied care. The cases suggest executive escalation can help in some disputes, but the report does not establish how often it works or whether it is a reliable route for other patients.
Two patients whose care had faced insurance barriers secured approvals after taking their cases to company executives, according to a MedPage Today report published Oct. 8. The accounts, highlighted by former insurance executive Wendell Potter, show that escalating a dispute to the C-suite may draw attention, but do not establish how often the approach succeeds.
One case involved Elizabeth Nicholas, who was diagnosed with breast cancer at age 36. After months of treatment, her insurer declined to cover the type of chemotherapy her oncologist recommended. Nicholas emailed the insurer’s CEO and soon received a message from its chief scientific officer saying the treatment had been approved. Her experience had also been covered in Vanity Fair the previous month, according to MedPage Today.
The other patient, Donald E. Grant Jr., 49, had severe congenital cervical stenosis. After an earlier operation did not adequately decompress his spinal cord, he developed myelomalacia, a condition involving damage to the spinal cord. Grant had scheduled surgery with Hyun Bae, a Cedars-Sinai spine surgeon, but Bae was outside his insurance network while other parts of the operation were in-network.
Grant used Claimable, an AI-assisted appeal platform, to prepare an 11-page appeal setting out medical and legal arguments, including that no in-network surgeon had comparable qualifications. He sent it to UnitedHealth Group’s CEO and copied company leaders, legislators and journalists. UnitedHealthcare then approved the procedure with Bae at the in-network rate, the report said. The account does not establish that the executive email alone caused the decision.
Executive Escalation Can Change a Case
The two accounts illustrate a possible route for patients whose requests have not been resolved through ordinary appeal channels. A message to senior leaders may prompt a company to review a high-profile dispute, particularly when it includes detailed medical documentation and is visible to journalists or public officials. But these are two reported success stories, not evidence that executive outreach routinely changes coverage decisions.
The cases also point to an imbalance in who can use this approach. Both patients spent time researching and documenting their cases, and Grant prepared an extensive appeal with help from a specialized platform. People with less time, support or knowledge of insurance procedures may find it harder to assemble similar materials. The report offers no data on the number of patients who contact executives, how many receive approvals, or how long the process takes.
As an affiliate, we earn on qualifying purchases.
How the Two Appeals Reached Leaders
Potter, a former insurance company executive, told MedPage Today that cases being examined by reporters were elevated when he worked at Cigna. He said insurers have staff who handle high-profile matters or cases sent to the C-suite or public-relations department. That description is Potter’s account of practices he observed; the report does not provide a response from Cigna or establish that every insurer handles escalated cases the same way.
The routes taken by the two patients differed. Nicholas’s experience had been reported publicly, while Grant built a written appeal citing regulations and the circumstances of his case before contacting UnitedHealth Group leadership. Both received approvals, but their stories do not show whether the same decisions would have followed from a standard appeal, a request for an exception, or other advocacy. The report also does not detail the insurers’ original reasoning for the decisions.
“You can be certain that at big insurance companies, there is a group of people around the CEO who are dedicated to high-profile cases and cases that are elevated to the C-suite or to the PR department — and they get special attention.”
— Wendell Potter, former insurance company executive, speaking to MedPage Today
As an affiliate, we earn on qualifying purchases.
Success Rate and Risks Remain Unknown
The report describes two successful cases, but does not provide a broader success rate or compare executive emails with formal appeals. It is unclear whether the approvals resulted chiefly from the medical and legal arguments, public attention, executive involvement, or a combination of factors. No timeline for either review is provided, and the original denial rationales are not fully detailed.
Patients may also face different rules depending on their plan and circumstances. The article does not establish that contacting a CEO changes appeal rights or deadlines, nor does it offer evidence that insurers retaliate against patients or clinicians for escalating concerns. Potter raised a possible professional risk for doctors who frequently challenge insurers, but that warning is not documented as a finding from these two cases.
As an affiliate, we earn on qualifying purchases.
Formal Appeals Still Matter
The report does not identify a scheduled follow-up, policy change or further company review connected to either approval. For now, the cases are examples of what happened to two patients, not a new insurer-wide policy. Patients facing a denial can use the appeal and review procedures that apply to their plan; the article does not suggest that an email to a CEO replaces those processes or their deadlines.
Potter said patients and clinicians should not treat an initial denial as the final answer, while acknowledging that escalation should not be necessary to obtain care. Further reporting would be needed to show whether executive outreach works consistently, how insurers review these messages and what protections or risks apply to patients and providers who use the tactic.
health insurance escalation letter
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What happened in the two cases?
Both patients received coverage approvals after contacting insurer leadership about care barriers. Nicholas’s chemotherapy was approved after she emailed her insurer’s CEO; UnitedHealthcare approved Grant’s surgery with an out-of-network surgeon at the in-network rate after he sent a detailed appeal to UnitedHealth Group’s CEO.
Does emailing an insurance CEO guarantee an approval?
No. The report describes two successful examples but gives no overall success rate and does not show that the same approach will work in other cases.
Did the CEO personally make the coverage decisions?
The report does not say that either CEO personally decided the case. Nicholas received a message from her insurer’s chief scientific officer, and the report says UnitedHealthcare approved Grant’s procedure after his escalation.
What risks did the report mention?
Potter warned that a doctor who frequently challenges an insurer could risk being removed from its network. This was a general caution from Potter, not a documented outcome in either patient’s case. The report does not identify a specific risk to patients who send executive emails.
Do executive emails replace a formal insurance appeal?
The report does not say they do. It describes executive outreach as an additional tactic and does not explain how it affects formal appeal procedures or deadlines. Those details were not established in the reported cases.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
